Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Filing Details

Accession Number:
0001209191-19-049007
Form Type:
4
Zero Holdings:
No
Publication Time:
2019-09-10 15:46:00
Reporting Period:
2019-09-06
Accepted Time:
2019-09-10 15:46:00
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1358762 Reata Pharmaceuticals Inc RETA Pharmaceutical Preparations (2834) 113651945
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1662520 Elaine Castellanos 2801 Gateway Drive
Suite 150
Irving TX 75063
Principal Accounting Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Class A Common Stock Acquisiton 2019-09-06 2,000 $0.00 4,138 No 4 C Direct
Class A Common Stock Disposition 2019-09-06 2,000 $85.00 2,138 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Class B Common Stock Employee Stock Option (right to buy) Disposition 2019-09-06 2,000 $0.00 2,000 $11.00
Class A Common Stock Class B common stock Acquisiton 2019-09-06 2,000 $11.00 2,000 $0.00
Class A Common Stock Class B common stock Disposition 2019-09-06 2,000 $0.00 2,000 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
37,434 2026-05-25 No 4 M Direct
2,000 No 4 M Direct
0 No 4 C Direct
Footnotes
  1. The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 7, 2019.
  2. The Class B common stock is convertible into Class A common stock on a one-for-one basis at the holder's election at any time. The conversion right of the Class B common stock has no expiration date.
  3. The options vest in sixteen equal quarterly installments beginning on August 25, 2016.